The RAS family of oncogenes (KRAS, HRAS, NRAS) are the most frequent mutations in 12 cancers and regulate key signaling pathways that drive tumor progression. As a result, drug 13 delivery targeting RAS-driven tumors has been a long-standing challenge in cancer therapy. 14 Mutant RAS activates cancer cells to actively take up nutrients, including glucose, lipids, and 15 albumin, via macropinocytosis to fulfill their energetic requirements to survive and proliferate. 16
in its inactive state. Upon stimulation by growth factor cues, GDP is released and RAS binds to 48 GTP, which subsequently activates downstream RAF/MEK/ERK signaling axis, resulting in cell 49 proliferation. RAS activation also spurs on PI3K and RalGDS effectors, which also stimulate cell 50 proliferation, migration, and survival 6 . Then, GTPase activation protein stimulates breakdown of 51 GTP via hydrolysis, producing GDP to bind and inactivate RAS. During tumorigenesis, specific 52 mutations of RAS cause constitutive RAS-GTP binding and subsequent constitutive activation of 53 downstream effectors resulting in uncontrollable cell proliferation and survival 6 . Here, oncogenic 54 4 RAS reprograms downstream signaling and alters cellular metabolism to fulfill the nutrient 55 requirements of these actively proliferating cancer cells. RAS-transformed cells activate 56 RAF/MEK/ERK signaling to increase glycolysis 7,8 , non-oxidative pentose phosphate pathway 7 , 57 and hexosamine biosynthesis pathways (reviewed in 9 ), which increase biomass synthesis 58 needed for cell survival and proliferation. In addition, cells have evolved to use available 59 sources of lipids, proteins, and nutrients for cell survival and proliferation. RAS-driven cancers 60 can scavenge nutrients intracellularly and extracellularly for their survival. Oncogenic RAS 61 proteins stimulate macropinocytosis in quiescent fibroblasts 10 and cancer cells [11] [12] [13] to "drink" in 62 surrounding bulk fluid and scavenger extracellular lipids and proteins. HRAS overexpressing 63 embryonic fibroblasts and RAS-transformed cells demonstrate increased membrane ruffling 64 characteristic of macropinocytosis and higher intracellular content of lysophospholipids 10, 14 . 65
Macropinocytosis is a fluid-phase endocytic process whereby cells form membrane ruffles upon 66 extracellular or intracellular cues, resulting in the formation of large diameter vacuoles (0.2 to 5 67 µm), or macropinosomes, that are able to transport solutes intracellularly 15, 16 . RAS-transformed 68 cells use the macropinocytosis program to fulfill their metabolic dependency to maintain their 69 growth and survival. Lipids, glutamine, and in particular albumin have been actively scavenged 70 by RAS-transformed fibroblasts, breast and pancreas cancers harboring activating RAS 71 mutations [11] [12] [13] 17, 18 . Collectively, these findings strongly indicate that albumin is actively 72 macropinoctyosed by RAS-transformed cells in vivo for metabolic needs. Towards this end, is it 73 feasible to exploit this vulnerability of nutrient transport to deliver drug carriers? 74
Attempts have been tried to delivery therapeutic payloads encapsulated in exosomes and 75 lipoprotein nanostructures to cancer cells via macropinocytosis [19] [20] [21] . We hypothesize that 76 albumin-based particles can exploit the macropinocytosis pathway of RAS-driven cancer cells 77 for intracellular delivery. Albumin has been used as a carrier to deliver different drugs for various 78 diseases including inflammation and cancer (reviewed in 22 ). In particular nab-paclitaxel, or 79 5 albumin-complexed paclitaxel, has been shown in combination therapy to improve overall 80 survival compared to monotherapy and is standard of care for the treatment of advanced 81 pancreatic cancer 23 . While albumin has been used, it has not been developed to actively 82 explicitly used in mechanistic, macropinocytosis-driven delivery into mutant KRAS-specific 83 cancers. Here, cross-linked albumin nanoparticles demonstrate enhanced uptake in oncogenic 84 RAS cells compared to control cells with wild-type RAS by non-ligand mediated 85 macropinocytosis. The physicochemical properties of the nanoparticles are tunable and they are 86 colloidally and physiologically stable. Interestingly, these particles exhibit greater uptake than 87 equivalent amounts of monomeric albumin (i.e. present in in vivo dissociated nab-paclitaxel). 88
Through microscopy-based quantification, these NPs co-localize in macropinosomes. Through 89 pharmacological inhibition and genetic knockdown experiments, we demonstrate that these NPs 90
can be endocytosed via RAS-driven macropinocytosis. These collective findings demonstrate 91 that the macropinocytosis pathway of oncogenic RAS cancer cells can be exploited for 92 nanoparticle delivery. By understanding this mechanism between the specific cancer pathway 93 and its impact on delivery, it will be feasible to develop drug carriers for pathway-specific, 94 targeted delivery. This work has the impact to greatly improve upon drug delivery and targeting 95 to RAS-driven cancers. 96
Materials and Methods 97

Synthesis of serum albumin nanoparticles 98
Nanoparticles were synthesized by modified desolvation methods [1] . Briefly, bovine serum 99 albumin (BSA, Fraction V, Fisher Scientific) was dissolved in 10 mM sodium chloride solution to 100 make a 1.5 % (w/v) BSA solution. The pH of the solution was adjusted to 9.0 with sodium 101 hydroxide. The desolvation agent was a mixture of methanol and ethanol at the ratio of 7:3 (v/v). 102
Then, 4 mL of the desolvation agent was added into 1 mL BSA solution using a syringe pump 103 (KD Scientific) at 1 mL/min under constant stirring. Subsequently, 8% glutaraldehyde solution 104 6 (Sigma-Aldrich) was added to the system to induce particle cross-linking. Cross-linking process 105 was allowed under stirring at room temperature for 12 hours. The synthesized nanoparticles 106 were washed with water for three times, using centrifugal filter membrane units (molecular 107 weight cutoff 100 kDa, Amicon). Fluorescent fluorescein isothiocyanate (FITC, ThermoFisher 108 Scientific) and Cyanine 7 (Cy7, Lumiprobe) was conjugated to monomeric BSA according to 109 manufacturer's protocol, respectively. Fluorescently labelled nanoparticles (FITC-NP and Cy7-110 NP) were synthesized by the same procedures as described above using FITC-BSA or Cy7-111 BSA instead of BSA. 112
Characterization of nanoparticles 113
The hydrodynamic diameter and zeta potential of the synthesized nanoparticles were 114 characterized using Zetasizer Nano ZS (Malvern) with 173˚ backscatter angle. The morphology 115 of the nanoparticles was observed by transmission electron microscope (TEM). Nanoparticles 116 solution was spread on a carbon coated grid and negatively stained with 2% uranyl acetate. The 117 grid was air-dried and then observed by TEM (FEI Tecnai). 118
Cell lines and cell culture 119
Human breast cancer cell lines, MDA-MB-231 harboring oncogenic KRAS mutation and MDA-120 MB-468 with wildtype KRAS, were purchased from American Type Culture Collection (ATCC). 121 DMEM/high glucose medium (Corning) supplemented with 10 % fetal bovine serum (Gibco) and 122 100 U/mL penicillin-streptomycin (Gibco) was used to maintain both cell lines. Cells were kept in 123 a humidified atmosphere with 5 % carbon dioxide at 37 ℃. 124
Measurement of intracellular uptake of nanoparticles by flow cytometry 125
MDA-MB-231 and MDA-MB-468 cells were seeded in 24-well plates at a density of 4×10 5 126 cells/well, respectively. After attachment, cells were starved in serum free medium overnight. To 127 compare the difference in uptake of monomeric albumin and nanoparticles, cells were 128 respectively incubated with FITC-BSA and FITC-NP for 2 hours at different concentrations of 129 7 0.5 mg/mL, 1.0 mg/mL and 1.5 mg/mL (equivalent amount of albumin). To evaluate the 130 inhibitory effect of macropinocytic inhibitor 5-(N-ethyl-N-isopropyl) amiloride (EIPA, Sigma-131 Aldrich) on the uptake of nanoparticles, cells were pre-treated with 25 µM, 50 µM and 75 µM 132 EIPA for 30 minutes, respectively. Then, cells were incubated with 500 µg/mL FITC-NP for 133 another 30 minutes. After each treatment, cells were placed on ice and washed with ice-cold 134 PBS for three times. Cells were collected in PBS buffer and stained with propidium iodide (PI, 135
Sigma-Aldrich). Samples were then analyzed by a flow cytometer (Accuri, BD Biosciences). PI-136 positive cells were excluded as dead cells. 137
Measurement of macropinocytic index 138
Macropinocytotic index was measured by an image-based method with slight modification [2, 3] . 139
Cells were plated in a 24-well plate with a circular cover glass in each well. Cells were incubated 140 with serum free medium overnight after reaching 60-70% confluency. The cells were incubated 141 with 1 mg/mL TMR-dextran in serum free medium for 30 min. After treatment, cells were 142 washed with ice-cold PBS for 5 times and fixed with 3.7% formaldehyde solution for 30 min at 143 room temperature. DAPI solution was added to stain the nucleus of the cells. The cover glass 144 was then placed cell side down onto a glass slide with a drop of mounting medium. Cell images 145 were randomly captured using an Olympus IX-83 inverted fluorescence microscope with a 100× 146 phase objective. A z-stack of frames throughout the entire height of cell monolayers was 147 aquored. The z-stack images were then collapsed to a single image using extended focus 148 imaging projection (CellSens 1.16). To calculate the macropinocytic index, the total cell area 149 was first selected from phase contrast images using the polygon selection tool of ImageJ. Then 150 the region of interest was applied onto the corresponding TMR-dextran image with thresholding 151 for macropinosomes. The total area of macropinosomes was computed. The macropinocytic 152 index was calculated as the following: macropinocytotic index = total area of 153 macropinosomes/cell number. 154
Colocalization of nanoparticles with macropinosomes 155
To quantify the colocalization of nanoparticle with macropinosomes, cells were plated in the 156 same way as described in the measurement of macropinocytic index. Then cells were incubated 157 with 1 mg/mL TMR-dextran and 1 mg/mL Cy7 labelled nanoparticles simultaneously. A group of 158 cells were treated with 25 µM EIPA to evaluate the effect of macropinocytic inhibition on 159 colocalization. After incubation, cells were fixed and sealed onto glass slides. Cell images were 160 captured using an Olympus IX-83 inverted fluorescence microscope with a 100× phase 161 objective. A z-stack of frames throughout the entire height of cell monolayers was acquired. The 162 z-stack images were then collapsed to a single image using extended focus imaging projection. 163
Background was subtracted with a constant of 1500. For each channel, the contrast was 164 adjusted to the same scale. The Pearson correlation coefficient (PCC) between pixels of TMR-165 dextran and pixels of Cy7 nanoparticles were analyzed by Cellsense 1.16 (Olympus). 166
Knockdown of KRAS protein expression and nanoparticle uptake 167
MDA-MB-231 cells were seeded in 6-well plates at a density of 1 × 10 6 cells/well. After 24 hours, 168 cells were transfected with siRNAs against KRAS gene (SMARTpool: Accell KRAS siRNA, 169
Dharmacon) at a final concentration of 0.5 µM, 1.0 µM and 1.5 µM in Accell siRNA delivery 170 media, respectively. A non-targeting siRNA was used as a negative control. 120 hours after 171 transfection, cells were harvested for western blot analysis. Cells were lysed using RIPA buffer 172 (Thermo Scientific) with protease inhibitor (Roche). The protein concentrations were determined 173 by BCA protein assay reagent kit (Thermo Scientific). Equivalent amounts of lysates (20 µg total 174 protein per lane) were loaded and separated by 10% SDS-PAGE (Invitrogen Bolt Bis-Tris Plus 175 gel). Then, proteins were transferred onto a low fluorescence PVDF membrane (Invitrogen). In 176 order to probe KRAS and β-actin separately, the membrane was cut into two pieces according 177 to the protein ladder and blocked with 5% non-fat milk. Then, the membranes were incubated 178 with anti-KRAS antibody (Abcam 55391) and anti-β-actin antibody (Sigma AC-40) at 4°C 179 overnight, respectively, followed by washing and incubating with secondary antibody (IRDye 180 9 800 CW, LI-COR) at room temperature for 2 hours. Finally, the protein bands were visualized 181 using Odyssey Clx imaging system (LI-COR). Densitometry measurements were calculated 182 using the gel analysis tool in ImageJ. 183
To evaluate the intracellular uptake of nanoparticles in cells with decreased KRAS expression, 184
MDA-MB-231 cells were seeded in 24-well plates and transfected with 1.0 µM and 1.5 µM 185
Accell siRNAs, respectively. 120 hours after transfection, cells were incubated with 500 µg/mL 186 FITC-NP for 30 minutes and subsequently analyzed by flow cytometry using the same method 187 as described above. 188
Statistical Analysis 189
All experiments were performed in triplicate at minimum. The results were expressed as means 190 ± standard deviation. Statistical significance was analyzed using Students' t-test for mean 191 differences among the samples. 37.60 ± 0.53 mV to -46.67 ± 0.32 mV. There is no obvious trend correlating particle size and 203 charge with the change of desolvation agent composition ( Figure 1B) . The nanoparticles 204 10 synthesized with desolvation agent of methanol: ethanol at the ratio of 3:7 (v/v) were chosen for 205 subsequent experiments. The mean size of cross-linked nanoparticles with this ratio was 69.78 206 ± 0.43 nm with PDI of 0.13 ± 0.01. The zeta potential of the nanoparticles was -42. 73 ± 1.20mV. 207 For subsequent studies to investigate cell uptake of particles, cross-linked albumin 208 nanoparticles (FITC-NPs) were prepared using fluorescently-labeled monomeric albumin to 209 ensure cross-linked nanoparticles had equivalent amount of FITC per albumin. The mean size 210 and zeta potential of the FITC-NPs were 71.41 ± 0.64 nm (PDI 0.10 ± 0.004) and -42.5 ± 0.36 211 mV, respectively. These measurements indicate that the conjugation of FITC to albumin prior to 212 nanoprecipitation of cross-linked NPs did not impact their physicochemical properties. Both non-213 labeled and FITC-labeled NPs were observed by transmission electron microscopy (Figure 2A  214 and Figure 2B , respectively). 215
The nanoparticles had a spherical morphology and were evenly distributed. To confirm 216 their physiological stability in vitro, particles were incubated in complete media with 10% FBS at 217 37˚C. The size and PDI of nanoparticles ( Figure 3A and 3B, respectively) had negligible change 218 up to 5 days, which confirms their serum stability. 219
Nanoparticles demonstrate higher uptake than monomeric albumin 220 Intracellular uptake of FITC-BSA and FITC-NPs was evaluated in MDA-MB-231 cells 221 with oncogenic KRAS mutation G13D ( Figure 4A ) and control MDA-MB-468 cells with wild-type 222 KRAS alleles ( Figure 4B ). Equivalent amounts of FITC-BSA and FITC-NPs were incubated, and 223 uptake of these fluorescent particles was quantified by flow cytometry. As shown in Figure 4 , the 224 mean fluorescence intensity (MFI) of FITC-BSA and FITC-NPs in both cell lines increased in a 225 dose-dependent manner. However, at each dose, the MFI of cells treated by FITC-NPs was 226 significantly higher than those of cells treated by FITC-BSA, which indicates that cross-linked 227
NPs demonstrate greater uptake than monomeric albumin. Subsequent experiments were performed to support that activating mutations of RAS stimulate 234 greater particle uptake than in cells with wild-type KRAS alleles. 235
Decreased KRAS protein expression resulted in reduced intracellular uptake of nanoparticles. 236
It was next tested if activating KRAS stimulates nanoparticle uptake in cancer cells. 237
MDA-MB-231 cells were transfected with siRNA targeting KRAS, and knockdown resulted in 238
decreased KRAS protein expression, as indicated by immunoblotting ( Figure 5A ). As shown in 239 Figure 5A , siRNA knockdown of KRAS in cells at different concentrations decreased KRAS 240 expression compared to non-targeting siRNA treated cells. Using densitometry to semi-quantify 241 protein expression, KRAS protein expression decreased to 50.4% with 1.5 µM siRNA treatment. 242
Subsequently, the intracellular uptake of FITC-NPs was determined in MDA-MB-231 cells with 243 siRNA-mediated knockdown of KRAS. As shown in Figure 5B , there was no difference between 244 cells without any treatment and cells treated with non-targeting siRNA. The addition of control 245 siRNA did not affect the uptake of FITC-NPs. However, the uptake of FITC-NPs was 246 significantly decreased in cells treated with KRAS targeting siRNAs, which indicates that direct 247 inhibition of KRAS can negatively impact uptake of FITC-NPs. This finding supports previous 248 studies that demonstrated hyperactivating RAS in cells stimulates their uptake of 249 macromolecules 10, 11, 13, 14 . 250
Elevated macropinocytosis of nanoparticle uptake in oncogenic KRAS cells. 251
12 It was then confirmed that oncogenic KRAS MDA-MB-231 exhibited increased 252 macropinocytosis compared to cells with wild-type RAS. The macropinocytic activity of MDA-253 MB-231 cells and MDA-MB-468 cells was visualized by imaging the uptake of 254 tetramethylrhodamine (TMR)-dextran, a fluorescent tracer for macropinocytosis. Here, TMR-255 dextran was internalized into cells via macropinosomes, shown as red puncta in Figure S1  256 (supplementary data). The amount of macropinosomes, which correlates with the extent of 257 macropinocytosis, was quantified by calculating their macropinocytic index, as developed by 258 Commisso et al. 27 . As shown in Figure S1 , the relative uptake of TMR-dextran in MDA-MB-231 259 cells was 2.5-fold higher than in MDA-MB-468 cells (p<0.01). Greater uptake of TMR-dextran in 260 oncogenic KRAS cells was due to macropinocytosis, as confirmed with pharmacological 261 inhibition of EIPA, a canonical inhibitor of macropinocytosis ( Figure S1 ). After treatment with 25 262 µM EIPA, the relative macropinocytic index of MDA-MB-231 cells significantly decreased 263 (p<0.01). However, there was no statistical difference in TMR-dextran uptake of MDA-MB-468 264 cells with or without EIPA ( Figure S1 ). These results confirm that mutant KRAS cancer cells 265 exhibit greater macropinocytosis than cells with wild-type KRAS alleles. 266
After confirming oncogenic KRAS MDA-MB-231 macropinocytoses reporter tracer TMR-267 dextran, it was next confirmed that the uptake of our cross-linked albumin nanoparticles is 268 inhibited by a similar mechanism. As shown in Figure 6A , when MDA-MB-231 cells were treated 269 with 25, 50, and 75 µM EIPA, the uptake of FITC-NPs were significantly inhibited by 16.79%, 270 21.50% and 16.03%, respectively. For MDA-MB-468 cells (Figure 6B) , the inhibition ratios were 271 6.09%, 9.39%, and 18.40%, respectively. A larger percentage of FITC-NPs was inhibited by 272 EIPA in MDA-MB-231 cells harboring oncogenic KRAS mutation compared to MDA-MB-468 273 cells with wild-type KRAS. The decrease in uptake due to the EIPA inhibition indicates that 274 cross-linked albumin NPs can be endocytosed by macropinocytosis, and this decrease is more 275 pronounced in mutant KRAS cells; this finding is comparable to other reports demonstrating 276 13 increased albumin uptake by oncogenic KRAS cancer cells and tumors via macropinocytosis 277 7, 11, 12 . 278
Colocalization of nanoparticles with macropinosomes in oncogenic KRAS cells 279
To further confirm that albumin NPs were present in macropinosomes, which are 280 indicative of macropinocytic uptake, Cy7 labelled nanoparticles were synthesized for the 281 colocalization analysis. The hydrodynamic size and zeta potential of Cy7 nanoparticles were 282 62.22 ± 0.55 nm and -45.70 ± 0.42 mV. Colocalization of Cy7 nanoparticles with TMR-dextran 283 was shown in Figure 7 . As shown in Figure 7A , Cy7 nanoparticles (green) and TMR-dextran 284 (red) were both taken up by mutant KRAS MDA-MB-231 cells. After treatment with EIPA ( Figure  285 7B), the amount of red and green puncta both decreased, indicating the uptake of TMR-dextran 286 and Cy7 nanoparticles was decreased. In Figure 7C and 7D, the uptake level of Cy7 287 nanoparticles and TMR-dextran were similar in MDA-MB-468 cells, regardless of the EIPA 288 inhibition. To determine the localization of albumin NPs in macropinosomes, we quantitatively 289 correlated the co-localization of NPs with TMR-dextran marker via image analysis and 290 calculation of the Pearson Correlation Coefficient (PCC). The PCC values between the two 291 channels were summarized in Figure 7E . The PCC value for MDA-MB-231 cells was 0.82, 292 which indicates good correlation of pixel intensity distribution between red and green channels. 293
After EIPA inhibition, the PCC value for MDA-MB-231 significantly decreased to 0.49 (p<0.05), 294 which means there was a significant decrease of nanoparticle uptake by macropinocytosis. The 295 relative low PCC values in MDA-MB-468 cells indicated that the Cy7 nanoparticles did not 296 colocalize well with TMR-dextran as those in MDA-MB-231 cells. In other words, the fraction of 297 nanoparticles taken up by macropinocytosis was lower than that in oncogenic KRAS MDA-MB-298
cells. 299
Discussions 300
14
Oncogenic RAS, the most abundant overall mutation in cancers, programs cell signaling 301 pathways and tumor progression; however, drugging this difficult-to-target oncoprotein has been 302 the promise and a long-standing goal in cancer therapy. Hyperactive RAS triggers intake of 303 extracellular nutrients needed for biogenesis, cancer cell survival, and proliferation to worsen 304 tumor progression. Studies demonstrated that mice with pancreatic tumors possessing KRAS 305 mutations demonstrated greater uptake of radiolabeled mouse serum albumin than healthy 306 pancreas and wild-type KRAS pancreatic cancers 11, 12 . This increased uptake of albumin has 307 also been previously observed with RAS-transformed fibroblasts 10,14 , glioblastoma 28 . Further, it 308 was found that scavenged and catabolized extracellular albumin was the only source of amino 309 acids present in oncogenic KRAS tumors and was needed for cancer cell proliferation and DNA 310 synthesis 12 . Davidson et al. confirmed that albumin was macropinocytosed by oncogenic KRAS 311 tumors and then degraded in lysosomes in vivo 12 . In addition to albumin and lipid uptake by 312 oncogenic KRAS cells via macropinocytosis [11] [12] [13] [14] 17 , it has been recently demonstrated that 313 larger-sized solutes, including antibodies 21 and lipoprotein nanoparticles 20 , also exhibit 314 increased uptake in active RAS-stimulated cells via micropinocytosis. Constitutively active RAS 315 stimulates intracellular uptake of lipids and proteins through the endocytic route of 316 macropinocytosis, which facilitates transport of large solutes in vesicles up to 5 µm in diameter. 317
Leveraging the metabolic needs of cancers for solute uptake via macropinocytosis, we wanted 318 to develop nanoparticles that specifically target this mechanism present in RAS-transformed or 319 oncogenic cancer cells towards drug delivery. Building on prior studies demonstrating albumin 320 uptake and catabolism in mutant KRAS cancers, we synthesized stable albumin nanoparticles 321 and tested their ability to enter oncogenic KRAS cancer cells for intracellular delivery. We 322 confirmed that albumin NPs exhibit significantly enhanced uptake in oncogenic KRAS cancer 323 cells compared with control cells with wild-type KRAS. Through extensive pharmacological 324 inhibition, genetic knockdown, and microscopy studies, we demonstrated hyperactivated KRAS 325 is responsible for stimulating macropinocytosis to engulf albumin NPs. By targeting oncogenic 326 RAS-driven macropinocytosis for delivery, there is no need for conjugated ligands on the drug 327 delivery system to facilitate cell binding and internalization. This simplicity of the 328 nanoprecipitation synthesis and lack of conjugation chemistries avoids the challenges of 329 chemistry and scalability and highlights the potential of this carrier for translation 29, 30 . While 330 future studies to confirm cell specificity are needed, these albumin nanoparticles exhibit 331 improved uptake in mutant RAS cancer cells compared to controls. Interestingly, albumin NPs 332 demonstrated significantly improved uptake compared to equivalent amount of albumin 333 monomers in cancer cell lines and in particular oncogenic KRAS MDA-MB-231 cells. The 334 current gold standard in albumin drug carriers, nab-paclitaxel, is a 130 nm paclitaxel-loaded 335 albumin nanoparticle in formulation 31 ; however, upon systemic administration, the particle 336 rapidly dissociates into albumin monomers equivalent to endogenous albumin, and the drug 337 prematurely releases, resulting in promiscuous accumulation in non-tumor tissues and organs 338 and off-target toxicities 18, 20, 26 . Coupled with the information that the cross-linked albumin NPs 339 are stable in serum for several days, these findings suggest that cross-linked albumin NPs could 340 deliver a higher amount of albumin and potentially, drug, than non-covalent, monomeric 341 albumin-associated nab-paclitaxel. Additional studies will be needed to confirm drug 342 encapsulation and stability of the cross-linked particles and compare its efficacy to nab-343 paclitaxel in cell culture and tumors. Finally, these nanoparticles were formulated to actively 344 target the macropinocytic pathway for intracellular uptake in oncogenic RAS cancers; to fulfill 345 the promise of these nanoparticles for RAS-targeted therapy, it will be necessary to extend 346 delivery to additional cancers with more canonical RAS mutations (e.g. KRAS G12V, G12C; 347 NRAS G12D) than the cells used in this current study and to use RAS-targeted therapeutics 348 such as covalent inhibitors 32, 33 There are no conflicts to declare in this work. 359 
